Divi's Laboratories — Q2 FY26
Divis Laboratories reported a strong Q2 FY26 with consolidated revenue of INR 2,860 crore (+17% YoY) and PAT of INR 689 crore (+35% YoY), driven by robust custom synthesis (56%...
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
FY26 Capex Guidance of INR 2,000 Crore
Management guided for total capital expenditure of INR 2,000 crore in FY26, directed at strategic projects, capacity expansion, and technology upgrades.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1